Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26080761 | 0.84 | POLB (0.58) | POLBATMKDM4EALDH1A1LMNA | |
| SCHEMBL28369391 | 0.82 | HRH3 (0.56) | KDM4EALDH1A1HRH3 | |
| SCHEMBL26078953 | 0.82 | ALDH1A1 (0.59) | POLBATMKDM4EALDH1A1LMNA | |
| SCHEMBL1126489 | 0.81 | SIGMAR1 (0.69) | POLBKDM4ELMNAHTTSIGMAR1 | |
| SCHEMBL24800866 | 0.81 | ALDH1A1 (0.47) | POLBATMKDM4EALDH1A1LMNA | |
| SCHEMBL348581 | 0.79 | LMNA (0.67) | KDM4EALDH1A1LMNAHRH3HDAC6 | |
| SCHEMBL349502 | 0.79 | ALDH1A1 (0.69) | POLBKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL20034212 | 0.79 | SIGMAR1 (0.68) | POLBALDH1A1LMNAPKMHTT | |
| SCHEMBL22906438 | 0.79 | NCF1 (0.67) | POLBATMKDM4EALDH1A1LMNA | |
| SCHEMBL22799479 | 0.79 | NCF1 (0.49) | POLBATMKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | POLB 2088/4885ATM 194/4885KDM4E 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.